-
Evusheld approved in EU for pre-exposure prophylaxis of COVID-19 in broad population
Time of Update: 2022-05-22
Evusheld clinical study results include data from the Phase III PROVENT pre-exposure prophylaxis trial, which showed a 77% reduction in the relative risk of symptomatic COVID-19 infection in subjects using Evusheld compared with placebo; median follow-up The 6-month analysis showed an 83% reduction in relative risk of symptomatic COVID-19 infection; protection persisted for at least 6 months .
-
Innovative CRISPR technology discovers genes that alter the tumor microenvironment and is expected to provide new anti-cancer targets
Time of Update: 2022-05-22
Combining in situ CRISPR screening with spatial transcriptomics, researchers at the Icahn School of Medicine at Mount Sinai in New York have identified genes that control lung cancer growth, respond to immunotherapy, and already regulate the tumor microenvironment.
-
Novartis' first-in-class drug Iptacopan to be included in breakthrough therapy
Time of Update: 2022-05-22
According to the Insight database, LNP023 is currently in the phase III clinical research and development stage in China, and clinical trials for the three indications of C3 glomerulopathy, IgA nephropathy, and paroxysmal nocturnal hemoglobinuria have all started phase III clinical trials .
-
Suffering as soon as you eat, what medicine can you take for oral ulcers to heal quickly?
Time of Update: 2022-05-22
In addition, a reasonable diet and balanced nutrition are also one of the key factors to protect and enhance the body's immunity, which is helpful for the prevention and recovery of ulcers .
-
Dupixent receives FDA priority review and is expected to gain new indications
Time of Update: 2022-05-22
S. Food and Drug Administration (FDA) has granted priority review status for the supplemental biological product application (sBLA) of the blockbuster IL-4/IL-13 inhibitor Dupixent (dupilumab).
References:[1] FDA Accepts Dupixent® (dupilumab) for Priority Review in Patients Aged 12 Years and Older with Eosinophilic Esophagitis.
-
The first general-purpose CAR-T in China was approved for clinical use from Beiheng Bio
Time of Update: 2022-05-22
CTA101 is the first “off-the-shelf” UCAR-T cell therapy product approved by CDE in China for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) .
It is reported that CTA101 adopts the "off-the-shelf" CAR-T cell therapy developed by Beiheng Bio's general CAR-T technology platform.
-
"Cell" important breakthrough!
Time of Update: 2022-05-22
Today, Cai Shang's research group from the School of Life Sciences of West Lake University published an article in "Cell", which not only reconfirmed the fact that bacteria exist in tumors, but also proved for the first time that unique intracellular bacteria in breast cancer play a key role in tumor metastasis and colonization .
-
Innovative FGFR inhibitor for the treatment of cholangiocarcinoma was granted priority review by the FDA
Time of Update: 2022-05-22
S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for futibatinib for the treatment of locally advanced or metastatic cholangiocarcinoma harboring FGFR2 gene rearrangements (including gene fusions).
-
Bacteria use methane to generate electricity
Time of Update: 2022-05-21
In a new publication, microbiologists at Radboud University demonstrate that it is possible to make methane-consuming bacteria generate electricity in the laboratory .
”a batteryColleagues microbiologists from Nijmegen have previously shown that it is possible to generate electricity using anammox bacteria, using ammonium instead of methane in the process .
-
What is causing the increase in black lung disease?
Time of Update: 2022-05-21
Journal Reference :Robert A Cohen, Cecile S Rose, Leonard HT Go, Lauren M Zell-Baran, Kirsten S Almberg, Emily A Sarver, Heather A Lowers, Cayla Iwaniuk, Sidney M Clingerman, Diana L Richardson, Jerrold L Abraham, Carlyne D Cool, Angela D Franko, Ann F Hubbs, Jill Murray, Marlene S Orandle, Soma Sanyal, Naseema I Vorajee, Edward L Petsonk, Rafia Zulfikar, Francis HY Green.
-
The GAS6/AXL inhibitor combination therapy introduced by Sidi Pharmaceuticals was approved for clinical use
Time of Update: 2022-05-21
On April 18, Sidi Medicine announced that its multi-center, open-label Phase 1b/2 clinical trial application for 3D229 injection combined with envolimab injection or lenvatinib in the treatment of advanced solid tumors was approved in China .
-
Soil water transport behavior caused by "funnel" canopy in banana orchards...
Time of Update: 2022-05-21
took banana orchards with different planting years as the research objects, and analyzed the soil water migration caused by the wide canopy and super- long leaves of banana orchards through controlled experiments on soil physical and hydrological properties.
-
Johnson & Johnson's "Daratumumab" new indication for listing
Time of Update: 2022-05-21
On April 15, the CDE official website showed that the new indication of Johnson & Johnson's daratumumab injection (subcutaneous injection) was applied for listing in China, and it is speculated that its indication may be multiple myeloma .
-
Bicyclic peptide conjugate therapy for bladder cancer achieves 50% objective response rate
Time of Update: 2022-05-21
▲Characteristic comparison of bicyclic peptides with small molecules and antibodies (Image source: Bicycle Therapeutics official website)In this clinical trial, 49% of patients with solid tumors who had received an average of 3 prior therapies and received different doses of BT8009 were patients with urothelial carcinoma .
-
Scientists discover anti-HIV-1 antibody treatment suppresses viral infection
Time of Update: 2022-05-21
Recently, researchers from The Rockefeller University published an academic paper titled "Prolonged viral suppression with anti-HIV-1 antibody therapy" in Nature, evaluating the effectiveness of repeated bNAb combination therapy to maintain long-term viral suppression and its impact on Influence of the size and composition of the latent virus reservoir in HIV-infected individuals .
-
Innovent Anti-IBI310 Included in Breakthrough Therapy Variety Combined with Sintilimab for Cervical Cancer
Time of Update: 2022-05-21
The breakthrough therapy designation of IBI310 is based on the results of an ongoing Phase 2 clinical study in patients with advanced cervical cancer (CDE registration number: CTR20202017) Phase 1 data .
-
Climate change is killing soil organisms vital to some of Earth's ecosystems
Time of Update: 2022-05-21
S. Geological Survey (USGS) researchers have traveled twice a year to 12 football-field-sized plots on the park's grass to assess the species and abundance of lichens, moss, fungi, microbes, and surrounding plants .
-
The research team made a major breakthrough in the induced pluripotent stem cell technology published in "Nature" today!
Time of Update: 2022-05-21
▲The development of a new generation of induced pluripotent stem cell technology (Image source: provided by the author of the study)Compared with traditional methods, the advantages of chemical small molecules include simple operation, strong temporal and spatial control, reversible effects, and highly controllable cellular reprogramming process .
-
The protective shield of cancer cells must be broken!
Time of Update: 2022-05-21
According to new research in the Proceedings of the National Academy of Sciences (PNAS), for immunotherapy to really work, it is necessary to address the protective environment that cancer cells create for themselves .
-
Largest-ever schizophrenia study published reveals genetic links to disease
Time of Update: 2022-05-21
Relevant research results were published online in the journal Nature Genetics on April 8, 2022, with the title "Exome sequencing in bipolar disorder identifies AKAP11 as a risk gene shared with schizophrenia" .
